Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12556857 | 0.92 | POLB (0.48) | MAPTALDH1A1KDM4ETP53MYC | |
| SCHEMBL12590171 | 0.83 | MAPT (0.45) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL241445 | 0.81 | MAPT (0.64) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL1837251 | 0.80 | MAPT (0.67) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL245326 | 0.77 | MAPT (0.64) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL244215 | 0.75 | MAPT (0.72) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL1837796 | 0.74 | MAPT (0.48) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL1837441 | 0.72 | MAPT (0.52) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL1826897 | 0.71 | ADH5 (0.54) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 | |
| SCHEMBL15714452 | 0.71 | MAPT (0.82) | MAPTALDH1A1KDM4EL3MBTL1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8691816-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | N30 PHARMACEUTICALS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | MAPT 3482/4885ALDH1A1 449/4885KDM4E 1572/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | MAPT 3482/4885ALDH1A1 449/4885KDM4E 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.